Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.
BTK Inhibitors in the Management of Lymphoma
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.